BDGENE

Shanghai, China · Founded 2018 · Privately Held (backing)

Developer of gene therapy drugs designed to cure eye diseases. BDGENE is based in Shanghai, China and was founded in 2018. It has raised $40 million.

Last price · $/share

—

Implied valuation

—

Total raised

$40.0M

Last round

—

Team — not yet on record

No current team members for BDGENE are on record yet. People surface from round filings, company disclosures, and coverage sessions.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of BDGENE with a free account

No card required

Membership and data by Private Market View